Table 2 Soluble markers of inflammation in plasma in the “rifaximin” (Rif, n = 20) and in the “no intervention” group (No Int, n = 20).
Marker | Group | Baselinea (n = 40) | 2 weeksa (n = 38) | 8 weeksa (n = 30) | P value interactionb |
|---|---|---|---|---|---|
CRPmg/L | No Int | 3.5 (2.1–7.1) | 4.7 (1.0–7.9) | 3.2 (2.5–6.9) | 0.029 |
Rif | 1.9 (0.86–4.80) | 2.20 (1.2–4.8) | 2.8 (1.9–5.4)* | ||
sCD14ng/mL | No Int | 3949 (3162–4456) | 4032 (3290–4630) | 3826 (2978–4459) | 0.555 |
Rif | 3378 (3072–4219) | 3639 (3241–4414) | 3552 (2921–4485) | ||
LPSpg/ml | No Int | 83 (78–91) | 86 (78–92) | 87 (78–94) | 0.955 |
Rif | 87 (80–96) | 90 (78–98) | 90 (83–102) | ||
sCD25ng/mL | No Int | 1.44 (0.71–2.10) | 1.54 (0.74–1.89) | 1.33 (0.80–1.86) | 0.636 |
Rif | 0.65 (0.51–1.43) | 0.63 (0.54–1.18) | 0.99 (0.44–1.55) | ||
sCD163ng/mL | No Int | 1699 (1350–2001) | 1677 (984–1930) | 1536 (1194–1940) | 0.320 |
Rif | 971 (647–1353) | 902 (749–1310) | 1151 (793–1549) | ||
Neopterinnmol/L | No Int | 11.18 (9.40–21.60) | 13.17 (8.32–24.31) | 10.37 (8.11–21.90) | 0.058 |
Rif | 9.02 (6.71–14.65) | 7.79 (6.37–17.24) | 11.43 (6.66–21.78) |
